Drug Profile
Research programme: Alzheimer's disease vaccine - Atlas Pharmaceuticals
Alternative Names: EB 101 - Atlas PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Atlas Pharmaceuticals
- Class Alzheimer vaccines; Antidementias; Neuroprotectants
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral, Liposomal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease(Prevention) in USA (Parenteral, Liposomal)